Physician profile
Thomas A Thorson
NPI 1942308614
$240,871.08
in general payments reported to CMS, 2019-2025
32 companies · $39K in 2025
The $39K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $35K · 2021: $35K · 2022: $36K · 2023: $26K · 2024: $35K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $96K · Food and Beverage: $3,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $95,550.00 |
| Food and Beverage | $3,779.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $200,392.16 | 2019-2025 | Trintellix |
| Shire North American Group INC | $33,800.00 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $1,169.98 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,042.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,000.04 | 2021-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $478.66 | 2019-2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $370.17 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.70 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Novo Nordisk INC | $305.48 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $271.24 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $244.07 | 2020-2025 | |
| Glaxosmithkline, LLC. | $210.54 | 2019-2025 | Nucala |
| Janssen Pharmaceuticals, INC | $171.72 | 2019-2023 | Spravato |
| Merck Sharp & Dohme LLC | $134.76 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $121.24 | 2022-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $103.79 | 2019-2020 | |
| Daiichi Sankyo INC. | $79.88 | 2022-2023 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $72.81 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $68.58 | 2022 | |
| Sanofi-Aventis U.S. LLC | $68.26 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.54 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $47.41 | 2020-2025 | Eliquis |
| Madrigal Pharmaceuticals | $42.17 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $40.37 | 2024-2025 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $39.87 | 2024 | Uptravi, Opsumit |
| Dexcom, INC. | $38.19 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $32.03 | 2025 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $32.02 | 2025 | |
| Exact Sciences Corporation | $31.93 | 2024 | Cologuard Collection Kit |
| Alkermes, INC. | $13.79 | 2023 | Lybalvi |
| Esperion Therapeutics, INC. | $12.40 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Thorson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.